Dr. Lisa Olshansky's lab focuses on understanding how structural changes in proteins can influence their functional properties, particularly in metalloenzymes. The research combines synthetic metal complexes with proteins that can change shape to create innovative models—called switchable artificial metalloproteins (swArMs)—to study these dynamics. This work aims to improve our understanding of enzyme behavior and ultimately develop new tools for biocatalysis, bioimaging, and energy conversion, all of which are crucial for human health.

Dr. Andrew Smith's lab focuses on developing innovative delivery systems for cancer therapies and obesity management. They are particularly interested in using nanocarriers for targeted treatment of metastatic breast cancer and advancing blood-based diagnostics for prostate cancer. Their work aims to improve health outcomes through personalized medicine by harnessing the body’s immune responses and minimizing side effects.

The lab led by Stephen G. Sligar at the University of Illinois focuses on understanding how membrane proteins work within lipid bilayers, which are essential for cell function. By using a special technology called Nanodiscs, which create small, stable environments that mimic natural cellular conditions, the lab explores how these proteins affect processes like hormone production and drug metabolism. This research aims to reveal the intricate mechanisms behind cell signaling and communication, key areas important for health and disease.

Dr. Adrienne Antonson's lab focuses on understanding how maternal influenza infections affect fetal brain development. They investigate the immune signaling pathways that cross from mother to fetus and how these affect the baby's brain. By using advanced techniques, the lab aims to find ways to mitigate the negative impacts of such infections, potentially leading to strategies that could protect both mothers and their unborn children from neurodevelopmental disorders.

Dr. David J. Shapiro's lab focuses on understanding a specific pathway that leads to necrotic cell death in cancer cells, especially in types resistant to traditional therapies. By studying how certain anticancer drugs trigger this process, the lab aims to uncover strategies to improve cancer immunotherapy and combat drug resistance. Their work combines advanced techniques such as CRISPR and mouse models to identify key proteins involved in cell death, which could help in developing more effective treatments for various cancers.

Dr. Fan Lam's lab focuses on developing advanced mass spectrometry techniques to study Alzheimer’s Disease. The research aims to create detailed molecular maps of the brain to better understand how brain chemistry changes in response to the disease and how neurogenesis might play a role in neuronal vulnerability and disease progression. By addressing the biochemical changes that occur in Alzheimer's, the lab hopes to identify potential biomarkers and therapeutic targets for this critical health issue.

Dr. Cunjiang Yu's lab at the University of Illinois focuses on developing innovative materials that support bone healing and regeneration. The lab's research looks into how light and electrically active materials can enhance the body's natural processes for repairing bone. By creating new biocompatible composites that combine citrate and electrosimulation, they aim to improve the effectiveness of orthopedic treatments.

Professor Martin D. Burke's lab at the University of Illinois focuses on innovative research in molecular prosthetics and automated synthesis of natural products. They aim to develop small molecules that can replace missing enzyme functions in humans, addressing diseases linked to enzyme deficiencies. Additionally, the lab is creating modular 'lego kits' for the automated synthesis of complex natural products like lipids and terpenoids, which have significant health and industrial applications.

Dr. Hua Wang's lab at the University of Illinois focuses on innovative approaches to modify and tag red blood cells (RBCs) for various biomedical applications. They aim to develop methods that allow for the direct engineering of RBCs in living organisms, which can enhance drug delivery, imaging, and immune responses. By leveraging the natural capabilities of RBCs, the research has the potential to transform how we use these cells in medicine.

Paul Hergenrother's lab focuses on developing new antibiotics to combat drug-resistant Gram-negative bacteria and on creating targeted cancer therapies. By understanding how drugs enter and exit bacterial cells, they aim to invent antibiotics that can effectively treat infections caused by difficult pathogens like E. coli. The lab also works on personalized cancer treatment by designing drugs that target specific abnormalities in cancer cells, advancing multiple promising drug candidates to clinical trials.

Dr. Satish K Nair's lab at the University of Illinois studies natural products called RiPPs, which are created from simple peptide sequences and have various medical applications. The lab focuses on understanding how certain enzymes transform these peptides into active compounds that can fight diseases like cancer and infections. By investigating the structure and function of these enzymes, the research aims to develop new and improved therapeutic drugs.

Professor Brian T. Cunningham's research lab focuses on developing an innovative system for testing viral infections such as HIV, Hepatitis B, and Hepatitis C using a compact and cost-effective device. Their goal is to create a rapid, easy-to-use test that can be performed at point-of-care sites, providing results in less than 30 minutes with minimal blood samples. This work aims to improve access to accurate viral load monitoring, which is crucial for managing these infections.